CA2590303C - Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b - Google Patents
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b Download PDFInfo
- Publication number
- CA2590303C CA2590303C CA2590303A CA2590303A CA2590303C CA 2590303 C CA2590303 C CA 2590303C CA 2590303 A CA2590303 A CA 2590303A CA 2590303 A CA2590303 A CA 2590303A CA 2590303 C CA2590303 C CA 2590303C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- lymphoma
- cells
- emab6
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001472 cytotoxic effect Effects 0.000 title description 16
- 231100000433 cytotoxic Toxicity 0.000 title description 7
- 230000035755 proliferation Effects 0.000 title description 3
- 230000003394 haemopoietic effect Effects 0.000 title description 2
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 76
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 56
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 42
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract description 37
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract description 37
- 239000000427 antigen Substances 0.000 claims abstract description 29
- 102000036639 antigens Human genes 0.000 claims abstract description 29
- 108091007433 antigens Proteins 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 23
- 208000032839 leukemia Diseases 0.000 claims abstract description 22
- 239000012642 immune effector Substances 0.000 claims abstract description 4
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 113
- 239000013598 vector Substances 0.000 claims description 48
- 238000011282 treatment Methods 0.000 claims description 35
- 241000282414 Homo sapiens Species 0.000 claims description 33
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 19
- 230000007170 pathology Effects 0.000 claims description 19
- 210000004698 lymphocyte Anatomy 0.000 claims description 15
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 13
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 8
- 210000003519 mature b lymphocyte Anatomy 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
- 102000013135 CD52 Antigen Human genes 0.000 claims description 3
- 108010065524 CD52 Antigen Proteins 0.000 claims description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 3
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 3
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 abstract description 73
- 229940079593 drug Drugs 0.000 abstract description 9
- 229960004641 rituximab Drugs 0.000 description 60
- 230000000694 effects Effects 0.000 description 21
- 108020004707 nucleic acids Proteins 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 21
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 20
- 230000009089 cytolysis Effects 0.000 description 19
- 102000000588 Interleukin-2 Human genes 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 15
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 15
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 12
- 239000012636 effector Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 229930182830 galactose Natural products 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000010432 diamond Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229960002378 oftasceine Drugs 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 101150074155 DHFR gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FZWIIGKQNLYDQI-UHFFFAOYSA-N 8-aminopyrene-1,3,6-trisulfonic acid Chemical compound C1=C2C(N)=CC(S(O)(=O)=O)=C(C=C3)C2=C2C3=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1 FZWIIGKQNLYDQI-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024292 Leukaemias acute Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 102100039641 Protein MFI Human genes 0.000 description 1
- 238000012180 RNAeasy kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000053350 human FCGR3B Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0413320 | 2004-12-15 | ||
| FR0413320A FR2879204B1 (fr) | 2004-12-15 | 2004-12-15 | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| PCT/FR2005/003123 WO2006064121A2 (fr) | 2004-12-15 | 2005-12-14 | Anticorps cytotoxique dirige contre les proliferations hematopoïetiques lymphoïdes de type b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2590303A1 CA2590303A1 (fr) | 2006-06-22 |
| CA2590303C true CA2590303C (fr) | 2015-05-26 |
Family
ID=34953790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2590303A Active CA2590303C (fr) | 2004-12-15 | 2005-12-14 | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9234045B2 (forum.php) |
| EP (2) | EP2949674A1 (forum.php) |
| JP (2) | JP4999699B2 (forum.php) |
| KR (3) | KR20120023177A (forum.php) |
| CN (1) | CN101115772B (forum.php) |
| AU (1) | AU2005315534B2 (forum.php) |
| BE (1) | BE2023C542I2 (forum.php) |
| BR (1) | BRPI0519044B8 (forum.php) |
| CA (1) | CA2590303C (forum.php) |
| DK (1) | DK1824887T3 (forum.php) |
| ES (1) | ES2588161T3 (forum.php) |
| FR (2) | FR2879204B1 (forum.php) |
| IL (1) | IL183947A0 (forum.php) |
| NL (1) | NL301242I2 (forum.php) |
| PL (1) | PL1824887T3 (forum.php) |
| WO (1) | WO2006064121A2 (forum.php) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7740847B2 (en) | 2004-08-04 | 2010-06-22 | Applied Molecular Evolution, Inc. | Variant Fc regions |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| FR2879605B1 (fr) * | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| EP2522395A1 (en) | 2005-02-03 | 2012-11-14 | TopoTarget UK Limited | Combination therapies using HDAC inhibitors |
| EP2494969B1 (en) | 2005-05-13 | 2015-03-25 | TopoTarget UK Limited | Pharmaceutical formulations of HDAC inhibitors |
| CN101282745B (zh) | 2005-07-25 | 2015-04-29 | 新兴产品开发西雅图有限公司 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
| US8828392B2 (en) | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
| FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
| EP1985633A1 (en) * | 2007-04-26 | 2008-10-29 | LFB Biotechnologies | Kit of parts for the treatment of cancer or infectious diseases |
| CA2700173C (en) | 2007-09-25 | 2016-10-11 | Topotarget Uk Limited | Methods of synthesis of certain hydroxamic acid compounds |
| ATE513856T1 (de) | 2008-04-11 | 2011-07-15 | Emergent Product Dev Seattle | Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| FR2940616A1 (fr) * | 2008-12-30 | 2010-07-02 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire. |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| FR2962908A1 (fr) * | 2010-07-20 | 2012-01-27 | Lfb Biotechnologies | Formulation d'anticorps anti-cd20 |
| FR2966043A1 (fr) * | 2010-10-14 | 2012-04-20 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif |
| EP4303237A3 (en) | 2010-11-30 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| FR2976811A1 (fr) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom |
| EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
| IN2015DN00139A (forum.php) * | 2012-07-13 | 2015-06-12 | Univ Pennsylvania | |
| PL3150256T3 (pl) * | 2012-11-02 | 2021-02-08 | Tg Therapeutics Inc. | Kombinacja przeciwciała anty-cd20 i selektywnego inhibitora kinazy pi3 |
| MX2018014256A (es) * | 2016-05-20 | 2019-08-16 | Harvard College | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. |
| BR112018074238A2 (pt) | 2016-05-27 | 2019-04-16 | Tg Therapeutics, Inc. | combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b |
| CA3035976A1 (en) | 2016-09-09 | 2018-03-15 | Tg Therapeutics, Inc. | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
| WO2022104150A1 (en) | 2020-11-12 | 2022-05-19 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| WO2025199155A1 (en) * | 2024-03-18 | 2025-09-25 | Tg Therapeutics, Inc. | Subcutaneous formulations of anti-cd20 antibody |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69303494T2 (de) * | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| RO120148B1 (ro) * | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
| US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| WO2004024768A2 (fr) | 2002-09-13 | 2004-03-25 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps induisant la production de cytokines |
| FR2844513B1 (fr) | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| SI1558648T1 (sl) | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
| HU227217B1 (en) | 2002-12-16 | 2010-11-29 | Genentech Inc | Immunoglobulin variants and uses thereof |
| CN1542132A (zh) * | 2003-04-30 | 2004-11-03 | 上海新霁生物科技有限公司 | 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
-
2004
- 2004-12-15 FR FR0413320A patent/FR2879204B1/fr not_active Expired - Lifetime
-
2005
- 2005-12-14 CA CA2590303A patent/CA2590303C/fr active Active
- 2005-12-14 KR KR1020127000194A patent/KR20120023177A/ko not_active Ceased
- 2005-12-14 AU AU2005315534A patent/AU2005315534B2/en active Active
- 2005-12-14 BR BRPI0519044A patent/BRPI0519044B8/pt active IP Right Grant
- 2005-12-14 PL PL05825974.8T patent/PL1824887T3/pl unknown
- 2005-12-14 EP EP15174374.7A patent/EP2949674A1/fr not_active Ceased
- 2005-12-14 KR KR1020137033324A patent/KR101418695B1/ko active Active
- 2005-12-14 JP JP2007546110A patent/JP4999699B2/ja active Active
- 2005-12-14 ES ES05825974.8T patent/ES2588161T3/es active Active
- 2005-12-14 CN CN2005800478101A patent/CN101115772B/zh active Active
- 2005-12-14 KR KR1020077015908A patent/KR101340192B1/ko active Active
- 2005-12-14 WO PCT/FR2005/003123 patent/WO2006064121A2/fr not_active Ceased
- 2005-12-14 EP EP05825974.8A patent/EP1824887B1/fr active Active
- 2005-12-14 DK DK05825974.8T patent/DK1824887T3/en active
- 2005-12-14 US US11/793,138 patent/US9234045B2/en active Active
-
2007
- 2007-06-14 IL IL183947A patent/IL183947A0/en active IP Right Grant
-
2011
- 2011-12-16 JP JP2011276347A patent/JP5693440B2/ja active Active
-
2015
- 2015-08-17 US US14/828,177 patent/US9873745B2/en active Active
-
2023
- 2023-09-14 NL NL301242C patent/NL301242I2/nl unknown
- 2023-10-20 FR FR23C1038C patent/FR23C1038I2/fr active Active
- 2023-11-21 BE BE2023C542C patent/BE2023C542I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2590303C (fr) | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b | |
| RU2656183C2 (ru) | Связывающие mica агенты | |
| EP3378487B1 (en) | Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function | |
| EP3277723B1 (fr) | Lignee cellulaire surexprimant l'antigene cd303 humain | |
| FR2940616A1 (fr) | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire. | |
| US20240409643A1 (en) | Anti-nmdar2b antibodies, antibody-drug conjugates, and chimeric antigen receptors, and compositions and methods of use | |
| US20240189424A1 (en) | Engineered natural ligand-based car: directed evolution of the stress-receptor nkp30 | |
| EP3498293A1 (en) | Treatment of monogenic diseases with an anti-cd45rc antibody | |
| FR2909092A1 (fr) | Nouveaux anticorps anti-proliferation | |
| EP3601342A1 (fr) | Anticorps dirigés contre un ligand d'un point de contrôle immunitaire avec fragment fc ayant une affinité améliorée pour cd16a | |
| EP3390452B1 (fr) | Nouvelle utilisation d'un anticorps dirige contre la proteine membranaire cd303 | |
| WO2012175874A1 (fr) | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom | |
| CA2661853A1 (fr) | Anticorps monoclonal dirige contre le recepteur humain des ldl | |
| EP2389954A1 (fr) | Anticorps cytotoxiques dirigés contre des anticorps inhibiteurs du facteur VIII | |
| WO2012049431A2 (fr) | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cérébral primitif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |